<DOC>
	<DOC>NCT02970929</DOC>
	<brief_summary>An extension study of safety and tolerability of SEP-363856 in adult subjects with schizophrenia</brief_summary>
	<brief_title>An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia</brief_title>
	<detailed_description>This is a 26 week, multiregional, open-label extension study designed to evaluate the long-term safety and tolerability of SEP-363856 for the treatment of subjects with schizophrenia who have completed the 4 week double-blind treatment phase of Study SEP361-201. No statistical hypothesis tests will be performed.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Subject must give written informed consent and privacy authorization prior to participation in the study and able to comply with the protocol, in the opinion of the investigator. Subject has completed Study SEP361 201 through Week 4 Subject has not taken any medication other than the study drug for the purpose of controlling schizophrenia symptoms during Study SEP361 201. Female subject must have a negative urine pregnancy test at Visit 7 of Study SEP361 201; females who are postmenopausal (defined as at least 12 months of spontaneous amenorrhea) and those who have undergone hysterectomy or bilateral oophorectomy will be exempted from the pregnancy test. Male subjects with female partner(s) of childbearing potential must agree to avoid fathering a child and use acceptable methods of birth control from screening until at least 30 days after the last study drug administration Subject answers "yes" to "suicidal ideation" Item 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) on the CSSRS assessment at Visit 7 of Study SEP361 201. Subjects who answer "yes" to this question must be referred to the Investigator for follow up evaluation. Subject has a clinically significant abnormality including physical examination, vital signs, ECG, or laboratory test at Visit 7 of Study SEP361 201 that the investigator in consultation with the medical monitor considers to be inappropriate to allow participation in the study. Subject has a positive urine drug screen (UDS) or breath alcohol test at Visit 7 of Study SEP361 201. Subject is pregnant or lactating. Subject is at high risk of noncompliance in the Investigator's opinion. Subject is in the opinion of the Investigator, unsuitable in any other way to participate in this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>